Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.

Novo Nordisk announced a new cash-pay option for its blockbuster weight-loss drug Wegovy, offering a monthly dose at $499 and home delivery. The move follows competitor Eli Lilly ...

Novo Nordisk is expanding its reach in the ... NovoCare will supply all dosage strengths of Wegovy in single-dose injection pens that will be shipped directly to a patient’s home.

Novo Nordisk, the manufacturer of Weggovy, is growing its offerings by creating NovoCare Pharmacy, a direct-to-patient (DTP) ...

Novo Nordisk's NovoCare will now provide uninsured or underinsured patients access to Wegovy for just $499 per month—less ...

Citing that there is unmet medical need in the country for the proposed indication, the Subject Expert Committee (SEC) ...

Novo Nordisk is providing direct-to-patient delivery ... Until recently, semaglutide injection products had been in short supply due to increased demand. During this time, compounded semaglutide ...